Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
PAQ Therapeutics secured $30 million in Series A financing to develop new therapeutics for diseases by enhancing the body’s ability to clear out damaged cells so it can regenerate newer, healthier ones.
The FDA has historically tended to keep more contentious relationships with some companies private. But recently, the agency appears to be publicly scolding some biopharma companies.
The next COVID pandemic could be prevented by using a gene drive to preemptively edit the genome of bats to prevent them from becoming hosts for coronaviruses, according to a proposal by scientists from Israel’s Interdisciplinary Center Herzelia and the National Institutes of Health.
Its lead product, WU-NK-101, is already proving itself in an ongoing Phase I/II trial, demonstrating an “impressive complete response rate in relapsed/refractory AML.”
The Biotech Bay region is home to 3,418 life sciences companies and 96,574 employees making an average of $148,285. Here’s a look at a few of the bay area biotech companies hiring now.
The device is at the core of the BRAVO trial, which evaluates signals to control complex devices for motor and speech in adults who have been severely affected by neurological disorders.
Biopharma and life sciences companies from across the globe provide updates on their business practices and pipelines.
In an interview with BioSpace, CEO Victoria Richon expressed her excitement about investor support and developing novel, first-in-class treatments.
Biden calls out the Health and Human Services department to submit a plan in the next 45 days to combat excessive drug prices and enhance domestic pharmaceutical supply chains.
The new CEO of Freenome has a talent for “making his own weather.” That’s a phrase he heard often growing up in Rapid City, South Dakota and, when applied to his life and career, comes down to assessing himself accurately and looking for opportunities to contribute.
Moderna CEO Stéphane Bancel believes the promise of mRNA vaccines is so great they will become a disruptive force in preventing viral infections.
Kriya Therapeutics, based in Redwood City, Calif. and Research Triangle Park, NC, closed on a Series B financing worth $100 million.
PRESS RELEASES
· Supporting the development of its proprietary MIC-Lx Modified Immune Cells technology as a novel approach to reduce lifelong systemic immunosuppression and improve long-term outcomes for transplant recipients · Strengthening MIC-Lx’s regulatory and commercial positioning in Europe
- EUR ~8M grant supports the late-stage clinical development of Omnix’s antimicrobial OMN6 - Leading European partners join forces to advance OMN6 for the treatment of life-threatening hospital-acquired infections